Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report released on Sunday morning. The firm issued a sell rating on the stock.

Oragenics Trading Down 2.7 %

NYSE:OGEN opened at $0.29 on Friday. Oragenics has a twelve month low of $0.25 and a twelve month high of $3.89. The firm has a market cap of $3.54 million, a price-to-earnings ratio of -0.04 and a beta of 0.38. The company has a 50-day moving average of $0.33 and a 200-day moving average of $0.49.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.